Practice patterns and resources are not well established for patients with less common cancers such as myelofibrosis. Community cancer programs may be challenged to keep up with evolving treatments, new anti-cancer medications, and the availability of clinical trials for patients with myelofibrosis.
Through a recent survey and needs assessment process, ACCC identified three member programs with expertise in treating patients with myelofibrosis. Read Effective Practices in Myelofibrosis Programs to gain insight into improving care delivery for patients with myelofibrosis.
The featured programs are serving as ACCC Community Resource Centers. ACCC members with less experience in caring for this patient population can contact any of these programs to ask questions and receive collaborative support in treating patients with myelofibrosis.
For a perspective on caring for this patient population, read Ask An ACCC Community Resource Center by Timothy Tyler, PharmD, FCSHP, of the Desert Regional Medical Center, Comprehensive Cancer Center, Palm Springs, Calif., an ACCC Community Resource Center for Myelofibrosis.
For more on treatment approaches to myelofibrosis, read A Focus on Primary Myelofibrosis from Rebecca Champion, PharmD, BCOP, and Don Stevens, MD, of the Norton Cancer Institute Hematologic Malignancies Program, Louisville, Ky., an ACCC Community Resource Center for Myelofibrosis.
Gain insight into primary myelofibrosis, including diagnosis, somatic mutations, common treatment options, and more. Also included in the article is a link to The Myeloproliferative Neoplasm Symptom Assessment Form.
Providers in smaller cancer programs may see just a few patients with myelofibrosis each year, keeping up with rapidly changing treatment options can be a challenge. Providers can contact ACCC Community Resource Centers for myelofibrosis to ask peer-to-peer questions and gain support.
Watch our video and learn more.